Simple updates to biosimilar labels are taking several months to receive US Food and Drug Administration approval, potentially affecting the growth of the fledgling sector.
Slow supplement approvals may not constitute a major problem at the moment, but as more biosimilars enter the market, the need to quickly change a label to stay in line...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?